Alumis Q3 2026 net loss narrows to $94.9M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alumis Inc. (ALMS) reported third-quarter 2026 financial results and clinical updates. Revenue for the three months ended September 30 was $1.907 million, compared with $2.066 million a year earlier; net loss was $94.881 million, compared with $110.752 million. For the nine months ended September 30, revenue was $5.310 million versus $22.121 million, and net loss was $330.155 million versus $150.394 million. Nine-month 2026 results included a $41.824 million intangible-asset impairment, while the 2025 period included a $187.907 million gain on bargain purchase.
Alumis said new Phase 3 envudeucitinib data showed improvements in plaque psoriasis, including a 54% PASI 100 response rate at Week 48. The company said its NDA submission for moderate-to-severe plaque psoriasis remains on track for 4Q 2026 and announced topline results from the LUMUS Phase 2b SLE trial. At September 30, 2026, Alumis reported $57.691 million in cash and cash equivalents and $373.647 million in current marketable securities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter net loss declined to $94.881 million from $110.752 million in 2025.
Negative
- Major pointNine-month net loss was $330.155 million, versus $150.394 million in 2025.
- Moderate pointNine-month revenue was $5.310 million, versus $22.121 million in 2025.
- Minor pointThird-quarter revenue was $1.907 million, versus $2.066 million in 2025.
8-K Event Classification
Key Figures
Key Terms
PASI 100 medical
tyrosine kinase 2 (TYK2) inhibitor medical
NDA regulatory
bargain purchase financial
intangible assets impairment loss financial
IFNGS-high subgroup medical
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ALMS’s third-quarter 2026 revenue and net loss?
What did ALMS report about envudeucitinib’s Week 48 psoriasis results?
AI-generated analysis. How Rhea-AI works. Not financial advice.
